Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688016's EV-to-FCF is ranked worse than 61.26% of 413
companies
in the Medical Devices & Instruments industry
Industry Median: 23.72
vs SHSE:688016: 30.10
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Microport Endovascular Medtech Co (SHSE:688016) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Microport Endovascular Medtech Co's PE Ratio (TTM) for today is calculated as:
Shanghai Microport Endovascular Medtech Co's share price for today is ¥94.20.
Shanghai Microport Endovascular Medtech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4.880.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shanghai Microport Endovascular Medtech Co EV-to-FCF Related Terms
Shanghai Microport Endovascular Medtech Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Microport Endovascular Medtech Co EV-to-FCF Chart
Shanghai Microport Endovascular Medtech Co Annual Data
SHSE:688016 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Shanghai Microport Endovascular Medtech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Microport Endovascular Medtech Co EV-to-FCF vs Medical Devices & Instruments Industry
Shanghai Microport Endovascular Medtech Co's current Enterprise Value is ¥9,480 Mil.
Shanghai Microport Endovascular Medtech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥312 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Microport Endovascular Medtech Co (SHSE:688016) has a EV-to-FCF of 30.39 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Microport Endovascular Medtech Co and its competitors. This is 58% below median its historical median of 72.58. According to the industry distribution chart, Shanghai Microport Endovascular Medtech Co ranks #253 out of 413 companies in the Medical Devices & Instruments industry, placing it in the top 61.3%.
Is Shanghai Microport Endovascular Medtech Co's EV-to-FCF too high?
Shanghai Microport Endovascular Medtech Co's current EV-to-FCF of 30.39 is 58% below median its 10-year median of 72.58. The Medical Devices & Instruments industry median EV-to-FCF is 23.72. Shanghai Microport Endovascular Medtech Co's value of 30.39 is 28.1% above this industry median. Based on the distribution chart, Shanghai Microport Endovascular Medtech Co ranks #253 out of 413 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Shanghai Microport Endovascular Medtech Co has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Microport Endovascular Medtech Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai Microport Endovascular Medtech Co ranks #253 out of 413 companies for EV-to-FCF. This places Shanghai Microport Endovascular Medtech Co in the lower half of its industry. The industry median EV-to-FCF is 23.72. Shanghai Microport Endovascular Medtech Co's value of 30.39 is 28.1% above this benchmark. While the company's 10-year median is 72.58 vs. the industry median of 23.72, Shanghai Microport Endovascular Medtech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.72, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Microport Endovascular Medtech Co's current EV-to-FCF of 30.39 is 28.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Microport Endovascular Medtech Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Microport Endovascular Medtech Co's current EV-to-FCF is 30.39, which is 58% below median its own 10-year median of 72.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Microport Endovascular Medtech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Microport Endovascular Medtech Co (SHSE:688016) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥120.05, compared to a current price of ¥94.20 — trading 21.5% below its estimated fair value. The current EV-to-FCF is 30.39, which is 58% below median its 10-year median of 72.58 and 28.1% above the Medical Devices & Instruments industry median of 23.72. Shanghai Microport Endovascular Medtech Co's overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shanghai Microport Endovascular Medtech Co (SHSE:688016), the current EV-to-FCF is 30.39 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Microport Endovascular Medtech Co (SHSE:688016) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Microport Endovascular Medtech Co stock appears to be undervalued.
The current stock price of ¥94.20 is trading 21.5% below its estimated GF Value™ of ¥120.05.
GuruFocus considers Shanghai Microport Endovascular Medtech Co to be Modestly Undervalued.
Key valuation signals for SHSE:688016:
EV-to-FCF: 30.39 (58% below median its 10-year median of 72.58)
GF Value™: ¥120.05 vs. price of ¥94.20 (21.5% below fair value)
Industry Position: 28.1% above the Medical Devices & Instruments median (#253 of 413)
No single metric tells the full story. See the SHSE:688016 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Microport Endovascular Medtech Co Business Description
Shanghai Microport Endovascular Medtech Co Ltd is engaged in the Research, development, production and sales of interventional medical devices for the aorta and peripheral blood vessels.
99GF Score
Get the complete analysis for SHSE:688016
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688016 has been successfully added to your 
